

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

**PRESCRIBER**

Name: .....

Ward: .....

**PATIENT:**

Name: .....

NHI: .....

**Enteral liquid peptide formula**

**INITIATION**

**Prerequisites** (tick boxes where appropriate)

☐ Patient has impaired gastrointestinal function and either cannot tolerate polymeric feeds, or polymeric feeds are unsuitable  
**and**

- ☐ Severe malabsorption  
**or**  
☐ Short bowel syndrome  
**or**  
☐ Intractable diarrhoea  
**or**  
☐ Biliary atresia  
**or**  
☐ Cholestatic liver diseases causing malabsorption  
**or**  
☐ Cystic fibrosis  
**or**  
☐ Proven fat malabsorption  
**or**  
☐ Severe intestinal motility disorders causing significant malabsorption  
**or**  
☐ Intestinal failure

- and**  
☐ The patient is currently receiving funded amino acid formula  
☐ The patient is to be trialled on, or transitioned to, an enteral liquid peptide formula

- and**  
☐ A semi-elemental or partially hydrolysed powdered feed has been reasonably trialled and considered unsuitable  
**or**  
☐ For step down from intravenous nutrition

Note: A reasonable trial is defined as a 2-4 week trial.

**CONTINUATION**

**Prerequisites** (tick boxes where appropriate)

- ☐ An assessment as to whether the patient can be transitioned to a cows milk protein or soy infant formula or extensively hydrolysed formula has been undertaken  
**and**  
☐ The outcome of the assessment is that the patient continues to require an enteral liquid peptide formula

I confirm that the above details are correct:

Signed: ..... Date: .....